Intravenous esomeprazole pharmacodynamics in critically ill patients

Current Medical Research and Opinion

Volumn 26, Issue 5, 2010, Pages 1141-1148

  Metz, David C ^a   Fulda, Gerard J ^b   Olsen, Keith M ^c   Monyak, John T ^d   Simonson, Steven G ^d   Sostek, M B ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Drug administration routes; Esomeprazole; Intensive care units; PH; Ulcer

Indexed keywords

ESOMEPRAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICALLY ILL PATIENT; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ENTERIC FEEDING; EXPLORATORY RESEARCH; FEMALE; GASTRIC SUCTION; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LABORATORY TEST; MALE; MULTICENTER STUDY; PHYSICAL EXAMINATION; RISK FACTOR; STOMACH PH; STRESS ULCER; UNITED STATES; UNIVERSITY HOSPITAL; VITAL SIGN;

ANTI-ULCER AGENTS; CRITICAL ILLNESS; HUMANS; OMEPRAZOLE;

EID: 77951060437     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007991003694308     Document Type: Article

References (24)

1. Sesler JM. Stress-related mucosal disease in the intensive care unit. An update on prophylaxis. AACN Adv Crit Care 2007;18:119-128
2. Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care 2005;20:35-45
3. Daley RJ, Rebuck JA, Welage LS, et al. Prevention of stress ulceration: current trends in critical care. Crit Care Med 2004;32:2008-2013
4. Cook DJ, Huller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994;330:377-381
5. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327
6. Spirt MJ, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse 2006;26:18-29
7. Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005;33:760-765
8. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: Pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 2005;39:1667-1677
9. Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. Am J Gastroenterol 1999;94:351-357
10. Pisegna JR, Sostek MB, Monyak JT, et al. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg in controlling intragastric acidity in healthy adults. Aliment Pharmacol Ther 2008;27:483-490
11. Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14:1267-1272
12. Miner Jr P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-2620
13. Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and phar-macokinetics of twice-daily esomeprazole: a randomized, three way crossover study. Aliment Pharmacol Ther 2004;20:399-406
14. Martin LF, Booth FV, Karlstadt BG, et al. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993;21:19-30
15. Wilder-Smith C, Rö hss K, Bondarov P, et al. Intravenous esomeprazole 40 mg is effective for the control of intragastric acid levels whether given as a 3-minute injection or a 30-minute infusion. Clin Drug Invest 2005; 25:517-525
16. Balaban DH, Duckworth CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically ill patients. Am J Gastroenterol 1997;92:79-83
17. Cloud ML, Offen W. Continuous infusions of nizatidine are safe and effective in the treatment of intensive care unit patients at risk for stress gastritis. Scand J Gastroenterol Suppl 1994;206:29-34
18. Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol 2007;102:2648-2654
19. Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006;101: 1964-1971
20. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254-260
21. Smith CL, Bardgett DM, Hunter JM. Haemodynamic effects of the i.v. administration of cimetidine or ranitidine in the critically ill patients. A double-blind prospective study. Br J Anaesth 1987;59: 1397-1402
22. Somberg L, Morris Jr J, Fantus R, et al. Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. J Trauma 2008;64:1202-1210
23. Tagamet [package insert]. Boronia, Australia: GlaxoSmithKline, 2007
24. Zegerid [package insert]. Whitby, Canada: Santarus, Inc.,2008